Medpace Holdings, Inc. (MEDP)

Medpace Holdings, Inc. is trading at $593.11, down 0.67% on the session. The 50 day average sits at $534.15 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 54.7, which reads as neutral, and MACD is bearish crossover. Volume is below average.

The nearest support is around $563.45 with resistance near $608.19, so that band frames the current range. Average daily movement is roughly $19.40, or about 3.3% of the share price, which is what any stop placement has to allow for. The overall health score of 57 out of 100 combines a trend score of 75, momentum of 48 and a risk score of 40.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.